Acta Pharmaceutica Sinica B Volume 12, Issue 12 Publishes
en-GBde-DEes-ESfr-FR

Acta Pharmaceutica Sinica B Volume 12, Issue 12 Publishes

22/12/2022 Compuscript Ltd
Publication title: Acta Pharmaceutica Sinica B (APSB)
Author: Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association
Publication type: Journal

https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b/vol/12/issue/12
Acta Pharmaceutica Sinica B (APSB) was founded with the goal of creating a global high-level forum centred around drug discovery and pharmaceutical research/application. APSB was included by Chemical Abstracts in 2011, accepted by PubMed Central in 2015, indexed by Science Citation Index in 2017 and has evolved to become one of the most important international journals in the field of pharmaceutical sciences.
APSB is a monthly journal, in English, which publishes significant original research articles, rapid communications and high-quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
Articles of interest in this issue include:

Evolution of drug regulations and regulatory innovation for anticancer drugs in China by Yang Liu, Ning Zhang, Cuicui Xie et al. (https://doi.org/10.1016/j.apsb.2022.08.004). This review is an overview of newly approved cancer drugs in China between 2005 and 2021, as a powerful illustration of how revolution in drug regulation has influenced the drug R&D in China.

Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein by Dongrong Yia, Quanjie Lia, Han Wang et al. (https://doi.org/10.1016/j.apsb.2022.05.023). Through structure-based virtual screening, this study reported that a natural compound berbamine hydrochloride can disrupt GPcl–NPC1 interaction, and strongly inhibited EBOV replication in vitro and in vivo.

Landscape of DILI-related adverse drug reaction in China Mainland by Jiabo Wang, Haibo Song, Feilin Ge et al. (https://doi.org/10.1016/j.apsb.2022.04.019). This study provides a whole epidemiological picture of L-ADR in mainland China and concluded that L-ADR has a persistent increase. This work provides a powerful tool to mine the potential hepatotoxic drugs in the future.

Other articles include:

Review Articles
Research and development of Chinese anti-COVID-19 drugs
Xiwei Ji, Xiangrui Meng, Xiao Zhu, Qingfeng He, Yimin Cui

Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, Huichang Bi, Jianjun Chen

Harnessing the cyclization strategy for new drug discovery
Kai Tang, Shu Wang, Wenshuo Gao, Yihui Song, Bin Yu

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, Huile Gao

Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era
Hao Ling, Xinyu Lou, Qiuhua Luo, Zhonggui He, ... Jin Sun

Research and development of Chinese anti-COVID-19 drugs
Xiwei Ji, Xiangrui Meng, Xiao Zhu, Qingfeng He, Yimin Cui

Small molecule-based immunomodulators for cancer therapy
Yinrong Wu, Zichao Yang, Kui Cheng, Huichang Bi, Jianjun Chen

Harnessing the cyclization strategy for new drug discovery
Kai Tang, Shu Wang, Wenshuo Gao, Yihui Song, Bin Yu

Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
Yanyan Xu, Jingyuan Xiong, Xiyang Sun, Huile Gao

Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era
Hao Ling, Xinyu Lou, Qiuhua Luo, Zhonggui He, ... Jin Sun

Original Articles
Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB /IL-6/STAT3 and JNK/PTX3 pathways
Wan Li, Hongqing Cai, Liwen Ren, Yihui Yang, ... Jinhua Wang

Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer
Minmin Fan, Jian Gao, Lin Zhou, Wenwen Xue, ... Qiang Xu

Fully synthetic Tn-based three-component cancer vaccine using covalently linked TLR4 ligand MPLA and iNKT cell agonist KRN-7000 as built-in adjuvant effectively protects mice from tumor development
Deying Yang, Xiang Luo, Qinghai Lian, Lingqiang Gao, ... Guochao Liao

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Chengliang Sun, Yao Cheng, Xiaojia Liu, Gefei Wang, ... Peng Yang

Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics
Qiang Niu, Yu Liu, Yujing Zheng, Ziwei Tang, ... Ping Zhao

Biodegradable calcium sulfide-based nanomodulators for H2S-boosted Ca2+-involved synergistic cascade cancer therapy
Chuchu Lin, Chenyi Huang, Zhaoqing Shi, Meitong Ou, ... Lin Mei

Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses
Nannan Wang, Yueyue Zuo, Shengjie Wu, Chenlu Huang, ... Dunwan Zhu

Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
Yuling Mao, Xiudan Wang, Caishun Chen, Qinfu Zhao, ... Siling Wang

Highlight
SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
Shujing Xu, Xinyong Liu, Peng Zhan

Commentary
Acute psychological stress redistributed leukocytes via distinct brain circuits
Yan-Ping Wu, Rong-Rong He

# # # # # #
The Journal of the Institute of Materia Medica, the Chinese Academy of Medical Sciences and the Chinese Pharmaceutical Association.
For more information please visit https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board

APSB is available on ScienceDirect (https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).

Submissions to APSB may be made using Editorial Manager® (https://www.editorialmanager.com/apsb/default.aspx).

CiteScore: 15.9
Impact Factor: 14.903
JIF without self-citation: 13.888

ISSN 2211-3835
# # # # #
22/12/2022 Compuscript Ltd
Regions: Europe, Ireland, Asia, China
Keywords: Health, Medical

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2023 by AlphaGalileo Terms Of Use Privacy Statement